Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Christian Rolfo et al.|The Lancet Oncology|2019Cited by 564
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trialNicholas C. Turner, Alistair Ring, Belinda Kingston et al.|The Lancet Oncology|2020Cited by 351
Genomic profile of advanced breast cancer in circulating tumour DNABelinda Kingston, Nicholas C. Turner, Rosalind Cutts et al.|Nature Communications|2021Cited by 95
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Joline S.J. Lim et al.|Cancer Discovery|2020Cited by 67